German preprint giving theory about why blood clots might rarely occur after vector-based COVID-19 vaccines
German preprint giving theory about why blood clots might rarely occur after vector-based COVID-19 vaccines
This explainer is more than 90 days old. Some of the information might be out of date or no longer relevant. Browse our homepage for up to date content or request information about a specific topic from our team of scientists.
This article has been translated from its original language. Please reach out if you have any feedback on the translation.
A preprint, an unpublished non-peer reviewed study, from researchers in Germany presents a theory for why vector-based COVID-19 vaccines, such as Oxford-AstraZeneca and Johnson & Johnson, may cause rare blood clots.
A preprint, an unpublished non-peer reviewed study, from researchers in Germany presents a theory for why vector-based COVID-19 vaccines, such as Oxford-AstraZeneca and Johnson & Johnson, may cause rare blood clots.
Publication
Vaccine-Induced Covid-19 Mimicry” Syndrome: Splice reactions within the SARS-CoV-2 Spike open reading frame result in Spike protein variants that may cause thromboembolic events in patients immunized with vector-based vaccines
Not peer-reviewed
Peer-reviewed
What our experts say
Context and background
Resources
Expert Comments:
Prof Jonathan Ball
It’s a really interesting hypothesis, that errant processing of the delivered spike gene results in the production of a truncated spike protein, which gets secreted from the cell, potentially triggering blood clotting events.
The data certainly highlights that production of this truncated spike may well occur, but it stops short of providing a concrete link with promotion of blood clotting. Nevertheless, it is certainly something worth investigating further.
